Intimation under Regulation 30 of SEBI(LODR) Regulations 2025.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Welcure Drugs & Pharmaceuticals has appointed Mr. Chintan Didawala Ganpat (DIN: 11088268) as Additional Executive Director of the company, effective May 6, 2025. The appointment was approved by the Board on the recommendation of the Nomination and Remuneration Committee and with the approval of the Audit Committee. His term is for five years, subject to shareholder approval at a general meeting. Mr. Ganpat brings experience in Finance and Management and is not related to any existing director on the board.
The addition of a finance and management experienced executive director may strengthen the company's leadership and governance. The appointment still requires shareholder ratification, which is a routine procedural step.